Table 2. Association between aberrant levels of lncRNAs and characteristics of patients with PCa.

Characteristics	Studies	Case number	Pooled OR (95% CI)	P	Heterogeneity		Model	References
					I2	P
Age (≤ 65 vs > 65 years old)	3	468	1.16 [0.45, 2.96]	0.76	19%	0.29	Random	[20, 22, 29]
Lymph node metastasis	8	1971	0.83 [0.48, 1.43]	0.50	64%	0.005	Random	[17–22, 29, 31]
Margin status	5	1478	1.15 [0.66, 2.02]	0.62	71%	0.007	Random	[17, 18, 21, 29, 31]
Preoperative PSA (≤ 10 vs > 10 ng/ml)	3	1011	1.12 [0.23, 5.37]	0.89	89%	0.0001	Random	[17, 18, 21]
SVI	2	1070	2.66 [0.21, 33.15]	0.46	89%	0.003	Random	[17, 31]
ECE/EPE	2	1067	1.30 [0.49, 3.45]	0.60	81%	0.02	Random	[17, 31]
Biochemical recurrence	3	491	2.06 [0.56, 7.57]	0.27	81%	0.005	Random	[19, 21, 31]
Distance Metastasis*	2	177	4.55 [2.26, 9.15]	< 0.0001	0%	0.86	Fixed	[20, 22]
Capsule invasion	2	177	1.36 [0.74, 2.50]	0.32	0%	0.47	Fixed	[20, 22]
Multiple lesions	3	334	0.95 [0.57, 1.58]	0.85	0%	0.82	Fixed	[20, 22, 31]
Tumor diameter (≤ 2.5vs > 2.5 cm)*	2	177	0.52 [0.28, 0.95]	0.03	0%	0.95	Fixed	[20, 22]
Gleason Score (< 7 vs ≥ 7)	8	2678	1.12 [0.54, 2.32]	0.75	82%	< 0.00001	Random	[17, 18, 20–22, 27, 29, 31]
Tumor stage (T2 vs T3-T4)	5	1536	0.88 [0.34, 2.29]	0.79	88%	< 0.00001	Random	[18, 20, 22, 27, 29]
Pathological stage (I + II vs III + IV)	3	1248	2.17 [0.88, 5.37]	0.09	85%	0.001	Random	[19, 21, 27]
Histological grade (II vs III + IV)*	2	177	6.23 [3.29, 11.82]	< 0.00001	0%	0.81	Fixed	[20, 22]

SVI = seminal vesical involvement; ECE = extra capsular extension; EPE = extra prostatic extension. “*” means P < 0.05.